

## Original article

## CC chemokine receptor 5 polymorphism in Italian patients with Behçet's disease

Fabiola Atzeni<sup>1,2</sup>, Luigi Boiardi<sup>3</sup>, Bruno Casali<sup>4</sup>, Enrico Farnetti<sup>4</sup>, Davide Nicolì<sup>4</sup>, Piercarlo Sarzi-Puttini<sup>1</sup>, Nicolò Pipitone<sup>3</sup>, Ignazio Olivieri<sup>5</sup>, Fabrizio Cantini<sup>6</sup>, Fabrizio Salvi<sup>7</sup>, Renato La Corte<sup>8</sup>, Giovanni Triolo<sup>9</sup>, Davide Filippini<sup>10</sup>, Giuseppe Paolazzi<sup>11</sup> and Carlo Salvarani<sup>3</sup>

## Abstract

**Objective.** To evaluate the potential role of CC chemokine receptor 5 (*CCR5*) $\Delta$ 32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients.

**Methods.** One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the *CCR5* $\Delta$ 32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations.

**Results.** The distribution of the *CCR5* $\Delta$ 32 genotype differed between BD patients and controls ( $P = 0.02$ ). The *CCR5* $\Delta$ 32 allele was more common in BD patients than in controls [ $P = 0.02$ , odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the *CCR5* $\Delta$ 32 allele ( $\Delta$ 32/ $\Delta$ 32 + *CCR5*/ $\Delta$ 32) were significantly more common in BD patients than in controls [ $P = 0.02$ , OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between *CCR5* $\Delta$ 32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between *CCR5* $\Delta$ 32 allele carriers and non-carriers.

**Conclusion.** *CCR5* $\Delta$ 32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD.

**Key words:** Behçet's disease, CC chemokine receptor 5  $\Delta$ 32 polymorphism, disease manifestations, chemokines.

## Introduction

Behçet's disease (BD) is a primary systemic vasculitis of unknown aetiology that may affect venous and arterial

vessels of any size [1]. The hallmark manifestation of BD is oral aphthosis, often associated with genital aphthae and various skin lesions [1]. Vascular, ocular and internal organ involvement occurs less frequently, but contributes substantially to morbidity and mortality [1]. Approximately one-third of BD patients develop thrombophlebitis of the deep or superficial veins (usually of the lower extremities), whereas arterial disease is distinctly less common (<5% of cases) [1, 2].

The pathogenesis of BD is still debated, but is likely to involve complex interactions between T cells, neutrophils and antigen-presenting cells [3]. In particular, mechanisms that may be operating include neutrophil hyperactivity [3], alteration of innate and adaptive immunity such as T helper 1 (Th1) [3, 4] and Th17 polarization [5] and excessive cytokine [4, 5] and chemokine production [4]. Chemokines and their receptors play an important role

<sup>1</sup>Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, <sup>2</sup>Rheumatology Department, Queen Mary University of London, UK, <sup>3</sup>Rheumatology Unit, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy, <sup>4</sup>Molecular Biology Laboratory, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy, <sup>5</sup>Rheumatology Unit, Ospedale S. Carlo, Potenza, Italy, <sup>6</sup>Rheumatology Unit, Ospedale Misericordia e Dolce, Prato, Italy, <sup>7</sup>Department of Neurological Sciences, Ospedale Bellaria, Bologna, Italy, <sup>8</sup>Rheumatology Unit, University of Ferrara, Ferrara, Italy, <sup>9</sup>Chair of Rheumatology, University of Palermo, Palermo, Italy, <sup>10</sup>Rheumatology Unit, Ospedale Niguarda, Milan, Italy and <sup>11</sup>Rheumatology Unit, Ospedale Santa Chiara, Trento, Italy.

Submitted 6 October 2011; revised version accepted 23 July 2012.

Correspondence to: Carlo Salvarani, Unità Operativa di Reumatologia, Azienda Ospedaliera ASMN, IRCCS, Viale Risorgimento 80, 42100 Reggio Emilia, Italy. E-mail: salvarani.carlo@asmn.re.it

in the selective recruitment of various subsets of leucocytes to affected sites in various autoimmune conditions [6].

In BD, increased expression of the Th1-associated CC chemokine receptor type 5 (CCR5) and CXCR3 has been demonstrated in mucosal samples, suggesting a pathogenic role for Th1 lymphocytes [4]. CCR5 is a G protein-coupled receptor expressed on Th1 cells, monocytes and dendritic cells [6]. CCR5 ligands include the chemokines CCL3 [chemokine (C-C motif) ligand 3, also known as macrophage inflammatory protein-1 $\alpha$ ], CCL4 (also known as macrophage inflammatory protein-1 $\beta$ ) and CCL5 [also known as RANTES (regulated on activation, normal T cell expressed and secreted)] [6]. CCR5 engagement by its ligands mediates mononuclear cell migration to sites of inflammation and has been implicated in the pathogenesis of various immune-mediated diseases [6]. CCR5 is also a major port of entry for macrophage-tropic HIV strains into host cells in association with CD4 [6]. The CCR5 gene polymorphism (a 32-bp deletion in the CCR5 gene CCR5 $\Delta$ 32) leads to a non-functional surface receptor that is unable to bind to its natural ligands [6].

The CCR5 $\Delta$ 32 allele has been linked to a number of immunological diseases, including RA and sarcoidosis [7–8]. With regard to BD, no association with the CCR5 $\Delta$ 32 polymorphism was found in British, Turkish or Palestinian patients [9], whereas an increased frequency of this polymorphic variant was found in Iranian patients [10]. The aim of our study was to investigate the potential impact of the CCR5 $\Delta$ 32 polymorphism on the susceptibility to and clinical expression of BD in a cohort of Italian patients.

## Materials and methods

### Study population

The study comprises 196 BD patients, recruited consecutively, who were followed in nine different Italian referral centres for 8 years (1999–2007). All patients fulfilled the International Study Group for BD (ISG) criteria [11]. The control group consisted of 180 healthy, age- and gender-matched, unrelated blood donors with a mean age of 42  $\pm$  13 years.

All study subjects were Caucasians who had been resident in Italy for at least one generation. There were no ethnic differences between patients and controls. The diagnosis of subcutaneous thrombophlebitis (ST) and deep vein thrombosis (DVT) was based on clinical data and confirmed in all patients by ultrasonography or contrast venography. In most of the patients with erythema nodosum, ultrasonographic examination was performed to help in the differential diagnosis between superficial thrombophlebitis and erythema nodosum. The study was approved by the ethics committees of Reggio Emilia, and written informed consent was obtained from patients and controls before study entry.

### HLA class I typing

A standard microlymphocytotoxicity technique was used to serotype HLA class I alleles in peripheral blood lymphocytes. One hundred and ninety-four of the 196 patients were typed for the HLA-B51 allele. The control group consisted of the same 180 healthy unrelated blood donors used for the CCR5 $\Delta$ 32 assays.

### Molecular analysis of CCR5 $\Delta$ 32 polymorphism

DNA extraction was performed using a Genomic DNA Purification Kit (Gentra Systems, Inc., Minneapolis, MN, USA) from peripheral white blood cells. Genotyping of CCR5 $\Delta$ 32 polymorphism comprised a one-step PCR method with forward primer 5'-TCTTCATTACACCTGCA GCTC-3' and reverse primer 5'-CTCACAGCCCTGTGCC TCTTC-3' flanking of the region containing the 32-bp deletion. The PCR products were analysed by 2.5% agarose gel electrophoresis. The normal allele was detected as a 137-bp fragment and the  $\Delta$ 32 allele was detected as a 105-bp fragment [12]. In each analysis, three samples with known genotype were added; the genotype control samples were confirmed each time, demonstrating that the procedure was highly reproducible.

### Statistical analysis

Statistical analysis was done using the SPSS statistical package (SPSS Inc., Chicago, IL, USA; version 14.0, 2006). The frequencies of the alleles and genotypes among the case patients and control group were compared by  $\chi^2$  test. Fisher's exact test was used when the minimum expected value was  $<$ 5. Odds ratios (ORs) were calculated together with their 95% CI. To determine *P*-values we used asymptotic lookup distribution with continuity correction. The cases and controls were tested for conformity to the Hardy-Weinberg equilibrium using a  $2 \times 2 \chi^2$  test between observed and expected numbers. To identify potential genotype-phenotype correlates, we compared patients with and without specific clinical manifestations according to CCR5 $\Delta$ 32 carrier status and compared with healthy controls.

The population-attributable risk percentage (PAR%) for the risk genotype ( $\Delta$ 32/ $\Delta$ 32 and CCR5/ $\Delta$ 32) was estimated with the following formula:

$$\text{PAR \%} = \text{Pe}(\text{RR} - 1) / [\text{Pe}(\text{RR} - 1) + 1],$$

where *Pe* represents the risk genotype frequency in the population and *RR* represents the relative risk of the risk genotype [13]. Given the low prevalence of BD, *Pe* can be estimated based on the genotype frequencies in healthy controls and *RR* can be approximated by OR for the risk genotypes. Power testing was performed using PAWE software: at a significance level of 0.05, power was 0.89 for the allelic test and 0.82 for the genotypic test (PAWE; <http://linkage.rockefeller.edu/pawe/pawe.cgi>).

## Results

Table 1 shows the demographic and clinical characteristics of the 196 Italian patients with BD. A total of 50

**TABLE 1** Demographic and clinical features of 196 Italian patients with BD: all patients and according to CCR5/Δ32 carrier status

Demographic/clinical features	BD (n = 196)	Δ32/Δ3 Δ32+ CCR5/Δ32 (n = 24)	CCR5/CCR5 (n = 172)	P
Mean age at disease onset (s.d.), years	30 ± 12			
Mean disease duration (s.d.), years	11 ± 8			
Male/female	103 (52.6)/93 (47.4)	11 (45.8)/13 (54.2)	92 (53.5)/80 (45.6)	0.482
Oral ulcers	196 (100)	24/24 (100)	172/172 (100)	0.102
Cutaneous lesions	161 (82.1)	20/24 (83.3)	141/172 (82.2)	0.871
Papulopustular lesions	105 (53.6)	13/24 (54.2)	92/172 (53.5)	0.950
Erythema nodosum	79 (40.3)	8/24 (33.3)	71/172 (41.3)	0.457
Genital ulcers	117 (59.7)	12/24 (50.0)	105/172 (61.0)	0.301
Epididymitis	14 (7.1)	2/24 (8.3)	12/172 (7.0)	0.809
Eye lesions	110 (56.1)	15/24 (62.5)	95/172 (55.2)	0.502
Anterior uveitis	62 (31.6)	7/24 (29.2)	55/172 (32.0)	0.782
Posterior uveitis/retinal vasculitis	85 (43.4)	11/24 (45.8)	74/172 (43.0)	0.795
Arthritis	82 (41.8)	8/24 (33.3)	74/172 (43.0)	0.367
Central nervous system involvement	32 (16.4)	6/24 (25.0)	26/171 (15.2)	0.225
Total venous thrombosis <sup>a</sup>	50 (25.5)	7/24 (29.2)	43/172 (25.0)	0.661
DVT	35 (17.9)	5/24 (20.8)	30/172 (17.4)	0.684
ST	20 (10.2)	5/24 (20.8)	15/172 (8.7)	0.066
Positive pathergy test <sup>b</sup>	42/101 (41.6)	4/10 (40.0)	38/91 (41.8)	0.915
HLA-B51 <sup>c</sup>	130/194 (67.0)	19/24 (79.1)	111/170 (65.3)	0.261

Data presented as number (%) unless otherwise noted. <sup>a</sup>DVT + ST. <sup>b</sup>Pathergy test performed on 101 patients. <sup>c</sup>HLA-B51 was performed on 194 patients.

patients (25.5%) had thrombosis, 35 of whom had DVT of the legs (17.9%) and 20 who had ST (10.25%). Two patients had isolated intracardiac thrombosis, and one had Budd-Chiari syndrome as well as extensive inferior vena cava and leg vein thromboses. None of the patients had arterial involvement. There were no significant differences in the demographic and clinical characteristics of the patients with and without DVT (data not shown). Populations of controls and cases were tested for Hardy-Weinberg equilibrium: genotype frequencies of all populations did not reject Hardy-Weinberg equilibrium.

The allele and genotype frequencies of the CCR5Δ32 polymorphism in BD patients and in healthy controls are shown in Table 2. The distribution of the CCR5Δ32 genotype differed significantly between BD patients and controls ( $P=0.024$ ). The distribution of the genotype in the CCR5Δ32 polymorphism indicated that the differences in allele distribution were related to a higher frequency of CCR5/Δ32 heterozygosity in BD patients as compared with controls. The Δ32/Δ32 homozygosity was not observed in either BD patients or in the control group. The CCR5Δ32 allele was significantly more common in BD patients than in controls [ $P=0.020$ ; OR 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5/Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more frequent in the BD patient group than in the control group [ $P=0.024$ , OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%.

Because one study [10] has shown that the influence of the CCR5Δ32 polymorphism could be gender specific, we

compared the distribution of the CCR5Δ32 allele in BD females and BD males. Carriers of the CCR5/Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in the BD females than in the control group [14% vs 5.6%,  $P=0.018$ , OR 2.76 (95% CI 1.2, 6.6)]. Carriers of the CCR5/Δ32 allele were also more common in BD males than in controls, but the difference was not statistically significant [10.7% vs 5.6%,  $P=0.091$ , OR 2.0 (95% CI 0.8, 5.0)].

The possible associations between the CCR5Δ32 polymorphism and the clinical manifestations of BD shown in Table 1 were evaluated in the 196 BD patients by comparing the frequencies of clinical manifestations between CCR5/Δ32 allele carriers and non-carriers; no significant differences were found. ST was more common in the carriers of the CCR5/Δ32 allele, but the difference was not statistically significant. HLA-B51 allele frequency was significantly higher in BD patients compared with healthy controls [67.0% vs 18.8%,  $P=0.0001$ , OR 8.72 (95% CI 5.4, 14.0)].

## Discussion

The CCR5 gene has a 32-bp deletion (Δ32) polymorphism in its promoter region resulting in a non-functional CCR5 protein [6]. CCR5Δ32 homozygous subjects do not express the receptor on the cell surface, whereas heterozygotes express lower amounts of the receptor than wild-type homozygotes [6]. In humans, CCR5Δ32 polymorphism has been linked to a wide range of diseases.

**TABLE 2** Frequency of alleles, genotypes and carriage rates of *CCR5Δ32* polymorphisms in patients with BD and in controls

Variable	BD (n = 196)	Controls (n = 180)	P	OR (95% CI)
Allele				
Δ32	24/392 (6.1)	10/360 (2.8)	0.020	2.28 (1.1, 4.8)
<i>CCR5</i>	368/392 (93.9)	350/360 (97.2)		
Genotype				
Δ32/Δ32	0/196	0/180	0.024	
<i>CCR5</i> /Δ32	24/196 (12.2)	10/180 (5.6)		
<i>CCR5</i> / <i>CCR5</i>	172/196 (87.8)	170/180 (94.4)		
Carriage rate				
Δ32/Δ32 + <i>CCR5</i> /Δ32	24/196 (12.2)	10/180 (5.6)	0.024	2.37 (1.1, 5.1)
<i>CCR5</i> / <i>CCR5</i>	172/196 (87.8)	170/180 (94.4)		

Values are the number/total number examined (%).

For some diseases, *CCR5Δ32* carriage appears to be a protective factor, being associated with a reduced risk in some rheumatic disease such as primary SS [14] and RA [7]. In contrast, other studies have mapped *CCR5Δ32* to increased susceptibility to or greater severity of inflammatory conditions such as chronic periaortitis [15], granulomatosis with polyangiitis [16] and sarcoidosis [8].

With regard to BD, one study found no association between the *CCR5Δ32* polymorphism and BD in British, Turkish or Palestinian patients [9], whereas another study reported an association between *CCR5Δ32* and BD in Iranian women, but not in men [10].

In our study, we found a positive association between the *CCR5Δ32* allele and BD in a large cohort of Italian patients. In categorizing patients according to gender, the association between *CCR5Δ32* polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). The reason for the discrepancies in the above findings is not entirely clear, but may be related to the sizes and types of the study populations. Sample size is a major issue in many studies investigating polymorphisms, with both type 1 and 2 errors being more likely to occur in smaller study populations. On the other hand, the association between the *CCR5Δ32* allele and BD may be a genuine finding, but limited to one or some ethnic groups. Either way, caution is advised when interpreting our results and those from previous studies [9, 10].

We could ask how the *CCR5Δ32* allele impacts on the susceptibility to develop BD. In wild-type individuals, *CCR5* mediates mononuclear cell recruitment to sites of inflammation by interacting with its ligands CCL3, CCL4 and CCL5. However, these ligands are also able to bind to other receptors. Specifically, CCL3 can also bind to *CCR1* and *CCR4*, CCL4 to *CCR1* and *CCR8*, and CCL5 to *CCR1*, *CCR3* and *CCR4* [6]. It has been shown that in the absence of a functional *CCR5*, its ligands can undergo up-regulation and exert their biological effects by engaging other available receptors. For instance, in nephrotoxic serum nephritis, *CCR5*-deficient (*CCR5*<sup>-/-</sup>) mice express higher intrarenal levels than wild-type strains of

CCL3 and CCL5, which appear to correlate with the infiltration of interferon- $\gamma$ -producing CD4<sup>+</sup> Th1 cells in the kidneys [17]. This Th1 response can be abrogated by *CCR1* blockade, suggesting that both CCL3 and CCL5 act by engaging *CCR1* [17–20]. Similarly, increased CCL4 synthesis has been described in *CCR5*<sup>-/-</sup> mice with collagen-induced arthritis [18], whereas in *CCR5*<sup>-/-</sup> mice with autoimmune uveoretinitis, overexpression of CCL5 has been linked to augmented intra-ocular production of IL-6 and greater neutrophil infiltration compared with wild-type mice [19]. Furthermore, it has been demonstrated that lymphocytes from *CCR5Δ32* homozygous subjects secrete RANTES at levels that are 5–10 times higher than those of control *CCR5* homozygous subjects [20]; the elevated levels of this chemokine can, by engaging other available receptors such as *CCR3* and *CCR1*, result in increased recruitment of inflammatory cells and production of pro-inflammatory cytokines within the inflammatory reactions. These findings are potentially relevant to the pathogenesis of BD, in which both a Th1-driven response and hyperactivation of neutrophils are thought to be crucially involved [3, 4]. Taken together, these data suggest that a genetically determined up-regulation of *CCR5* ligands may be implicated in the pathogenesis of vascular inflammation in BD.

A second aim of this study was to determine whether *CCR5Δ32* polymorphism might be associated with the clinical expression of BD in our cohort of Italian patients. However, when the frequencies of clinical manifestations were compared between *CCR5Δ32* allele carriers and non-carriers, no differences were found, although our study is probably not sufficiently powered to detect significant associations between this *CCR5* polymorphism and clinical manifestations.

In conclusion, the results of this study suggest that the *CCR5Δ32* polymorphism may increase the susceptibility to BD in Italian patients. Further studies are required to replicate our findings in other populations and to better elucidate the role of chemokines in the inflammatory events leading to vascular injury in BD.

## Rheumatology key messages

- The CCR5Δ32 polymorphism may be associated with an increased risk of developing Behçet's disease (BD) in the Italian population.
- An association of CCR5Δ32 with subcutaneous thrombophlebitis in patients with BD has been found but was not statistically significant.
- Chemokines may have a role in the pathophysiology of BD.

**Funding:** This study was supported by grants from the Rheumatology Department of Reggio Emilia.

**Disclosure statement:** The authors have declared no conflicts of interest.

## References

- 1 Yazici Y, Yurdakul S, Yazici H. Behçet's syndrome. *Curr Rheumatol Rep* 2010;12:429–35.
- 2 Seyahi E, Yurdakul S. Behçet's syndrome and thrombosis. *Mediterr J Hematol Infect Dis* 2011;3:e2011026.
- 3 Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. *Clin Rheumatol* 2010;29:1211–6.
- 4 Houman H, Hamzaoui A, Ben Ghorbal I *et al.* Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. *J Autoimmun* 2004;23:267–73.
- 5 Leng RX, Chen GM, Pan HF, Ye DQ. The role of IL-23/IL-17 axis in the etiopathogenesis of Behçet's disease. *Clin Rheumatol* 2010;29:1209.
- 6 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med* 2006;354:610–21.
- 7 Prahald S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. *Genes Immun* 2006;7:264–8.
- 8 Petrek M, Drabek J, Kolek V *et al.* CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. *Am J Respir Crit Care Med* 2000;162:1000–3.
- 9 Yang X, Ahmad T, Gogus F *et al.* Analysis of the CC chemokine receptor 5 (CCR5) delta32 polymorphism in Behçet's disease. *Eur J Immunogenet* 2004;31:11–4.
- 10 Mojtahedi Z, Ahmadi SB, Razmkhah M *et al.* Association of chemokine receptor 5 (CCR5) delta32 mutation with Behçet's disease is dependent on gender in Iranian patients. *Clin Exp Rheumatol* 2006;24:S91–4.
- 11 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet* 1990;335:1078–80.
- 12 Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptors in type 1 diabetes mellitus and its complications. *Cytokine* 2004;26:114–21.
- 13 Schildkraut JM. Examining complex genetic interactions. In: Haines JL, Pericak-Vance MA, eds. *Approach to gene mapping in complex human diseases*. New York, NY: Wiley-Liss, 1998:379–410.
- 14 Petrek M, Cermáková Z, Hutýrová B *et al.* CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjögren's syndrome. *Clin Exp Rheumatol* 2002;20:701–3.
- 15 Boiardi L, Vaglio A, Nicoli D *et al.* CC chemokine receptor 5 polymorphism in chronic periaortitis. *Rheumatology* 2011;50:1025–32.
- 16 Zhou Y, Huang D, Farver C, Hoffman GS. Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. *J Rheumatol* 2003;30:1541–7.
- 17 Turner JE, Paust HJ, Steinmetz OM *et al.* CCR5 deficiency aggravates crescentic glomerulonephritis in mice. *J Immunol* 2008;181:6546–56.
- 18 Bao L, Zhu Y, Zhu J, Lindgren JU. Decreased IgG production but increased MIP-1beta expression in collagen-induced arthritis in C-C chemokine receptor 5-deficient mice. *Cytokine* 2005;31:64–71.
- 19 Takeuchi A, Usui Y, Takeuchi M *et al.* CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. *Invest Ophthalmol Vis Sci* 2005;46:3753–60.
- 20 Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. *Semin Immunol* 1998;10:187–94.